HVT Medical

Company Overview

Snapshot

Founded in January 2022, HVT Medical operates with 1–10 employees. The company has raised $1.5 million across two funding rounds, with Israel MedicUp as an investor. In January 2024, HVT Medical secured a grant from the Israel Innovation Authority.

Business overview

HVT Medical is developing innovative solutions for patients with anatomical limitations preventing aortic valve implantation. The company's core product, The Splitter, is a transcatheter device designed to modify the aortic valve through cusp splitting before a TAVI procedure, thereby reducing the risk of coronary occlusion. HVT Medical primarily serves the healthcare and life sciences sectors, focusing on medical devices and medical treatment therapeutics.

Company Intelligence Q&A

What is HVT Medical's primary focus?

HVT Medical focuses on developing solutions for patients contraindicated for aortic valve implantation due to anatomical limitations, specifically in the cardiology and medical device sectors.

When was HVT Medical founded?

HVT Medical was founded in January 2022.

What is The Splitter device?

The Splitter is a device developed by HVT Medical that can be inserted in a catheterization procedure to modify the aortic valve. It performs cusp splitting before a TAVI procedure to reduce the risk of coronary occlusion by creating an intentional laceration or excision of the valve's cusp tissue using an advanced catheter with a cutting head.

How much capital has HVT Medical raised?

HVT Medical has raised $1.5 million across two funding rounds.

Did HVT Medical receive any grants?

In January 2024, HVT Medical secured a grant from the Israel Innovation Authority.